Not So Different: A Podcast From The Center For Biosimilars

S6 Ep11: Biosimilars Immunology Roundup for May 2023—Podcast Edition

Informações:

Sinopsis

Show Notes FDA Approves Celltrion’s Yuflyma, the Ninth Adalimumab Biosimilar Celltrion Launches Biobetter in Brazil, Shares Phase 3 Plan for MS Biosimilar Amgen’s Stelara Biosimilar Delayed Until 2025 After Settling With J&J Dr Colby Evans: The Managed Care Perspective on Biosimilars in Immunology Dr Vibeke Strand: The Current State of Immunology Biosimilars and the Promise of Future Savings   Samsung Bioepis Report Correlates Biosimilar Pricing Changes With Market Adoption Biosimilars Business News Recap: A New Partnership; Celltrion Wins Tenders Tocilizumab Biosimilar LZM008 Demonstrates PK Equivalence in Healthy Participants RWE: Rituximab Biosimilar GP2013 Effective in Patients With RA After Switching From Originator